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Abstracts

PTCH1, BCOR, CLIC6, TLL2, COL1A1, PTPRK). Notably, mutations in
BCOR and PTCH1 have been previously implicated in both systemic neuroendocrine tumors as well as primary tumors of the pituitary gland, while
MYO18A, FGF4, and PTPRK mutations had not been reported in systemic
neuroendocrine tumors but have been implicated in tumor migration and
pituitary adenoma progression. In summary, these data demonstrated an expected mutational pattern indicating a systemic lung neuroendocrine origin
but also revealed new mutations previously implicated in primary pituitary
pathologies that may have evolutionarily drove divergence from the primary
tumor. Further genome studies of these rare lesions may yield further insight
into the genetic alterations underlying metastasis to the sellar region.
29. ROLE OF AGE AND CNS MYELOID CELLS ON BREAST CANCER
BRAIN METASTASIS
Alex Man Lai Wu1, Selamawit Gossa2, Ramakrishna Samala3,
Monika Chung1, Brunilde Gril1, Howard Yang1, Helen Thorsheim4,
Andy Tran1, Debbie Wei1, Kristine Isanogle5, Yuan Yang1, Emma Dolan1,
Christina Robinson5, Simone Difilippantonio5, Maxwell Lee1,
Quentin Smith4, Dorian McGavern2, Lalage Wakefield1, and Patricia Steeg1;
1National Cancer Institute, Bethesda/MD, USA, 2National Institute of
Neurological Disorders and Stroke, Bethesda, MD, USA, 3South University,
Columbia, SC, USA, 4Texas Tech University Health Sciences Center,
Amarillo, TX, USA, 5National Cancer Institute, Frederick, MD, USA
Women diagnosed with breast cancer at a younger age (typically defined
as < 40 years old) often have a poorer prognosis and an increased risk of
brain metastasis compared to their older counterparts. Multivariate analyses accounting for differences in tumor characteristics have shown that age
is an independent predictor of worse outcome. We therefore hypothesized
that rather than intrinsic tumor properties, extrinsic microenvironmental
factors contribute to age-related differences in aggressiveness. The effect of
age was examined by injecting brain-selected breast cancer cells into young
(2 – 6 months) and older (>12 months) mice. In four brain metastasis models
examined, young mice developed 2- to 16-fold (p < 0.05) more brain metastases compared to older mice. The effect of age was not observed in mouse
breast cancer models that metastasize to liver and lungs, suggesting that this
is an organ-specific phenomenon. Flow cytometry-based immune-profiling
of mouse brains showed that T-cells (CD4+, CD8+, and FOXP3+CD25+
regulatory T-cells), monocytes and neutrophils were elevated in brains with
metastases, but the abundance of these populations did not vary dramatically with age. Furthermore, antibody-based depletion of T-cells, monocytes
and neutrophils did not significantly alter brain metastasis development.
Microglia, which are resident CNS myeloid cells, were 1.5-fold more abundant in young brains compared to older brains. Depletion of CNS myeloid
cells using the colony stimulating factor-1-receptor inhibitor PLX3397 reduced brain metastatic tumor burden in young mice by 2.1-fold (p < 0.001).
Importantly, loss of CNS myeloid cells/microglia, which are normally more
activated in aged mice and thus may protect the older brain against metastasis, did not augment brain metastasis formation in older mice. These
results suggest that the younger brain is more permissive for breast cancer
metastasis and that targeting resident CNS myeloid cells may be an effective
strategy to prevent brain metastasis development in younger patients.
30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS
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1Miami Baptist Cancer Center, Miami, FL, USA, 2Northwestern Medicine
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BACKGROUND: Tumor Treating Fields (TTFields) are non-invasive,
loco-regional, anti-mitotic treatment modality comprising alternating electric fields. TTFields have demonstrated efficacy in preclinical non-small cell
lung cancer (NSCLC) models. TTFields treatment to the brain was safe and
extended overall survival in newly-diagnosed glioblastoma. The objective of
the METIS study [NCT02831959] is evaluation of the efficacy and safety of
TTFields in NSCLC patients with brain metastases. METHODS: NSCLC
patients (N=270) with 1–10 brain metastases were randomized 1:1 to stereotactic radio surgery (SRS) followed by continuous TTFields ((150 kHz, > 18
hours/day) within 7 days of SRS or supportive care. The portable device
delivered TTFields to the brain using 4 transducer arrays, while patients
received the best standard-of-care for systemic disease. Patients were followed every two months until second intracranial progression. Key inclusion criteria: KPS ≥70, new diagnosis of 1 inoperable or 2–10 supra- and/or
infratentorial brain metastases from NSCLC amenable to SRS; and optimal
therapy for extracranial disease. Prior WBRT, surgical resection of metastases, or recurrent brain metastases were exclusionary. Primary endpoint
was time to 1st intracranial progression. Secondary endpoints included
time to neurocognitive failure (HVLT, COWAT and TMT), overall survival,

radiological response rate (RANO-BM and RECIST V1.1); quality-of-life;
adverse events; time to first/second intracranial progression for patients with
1–4 and 5–10 brain metastases; bi-monthly intracranial progression rate
from 2–12 months; and time to second intracranial and distant progression.
The sample size (N=270) was calculated using a log-rank test (Lakatos 1988
and 2002) with 80% power at two sided alpha of 0.05 to detect a hazard
ratio of 0.57. On September, 2019, an independent Data Monitoring Committee (DMC) reviewed METIS trial data collected to that point. The DMC
concluded that no unexpected safety issues had emerged and recommended
continuation of the METIS study as planned.
31. RADIATION NECROSIS IN STEREOTACTIC RADIOSURGERY
AND CHECKPOINTS INHIBITORS FOR BRAIN METASTASES FROM
LUNG ADENOCARCINOMA
James Jurica1,2, Shraddha Dalwadi1,2, David Baskin2, Eric Bernicker2,
Brian Butler2, Robert Rostomily2, Bin Teh2, Ivo Tremont-Lukats2, and
Andrew Farach2; 1Baylor College of Medicine, Houston, TX, USA,
2Houston Methodist Hospital, Houston, TX, USA
PURPOSE: Treatment with stereotactic radiosurgery (SRS) and immune
checkpoint inhibitors (ICI) is increasingly common for brain metastases
(BM) from lung adenocarcinoma. Rates of radiation necrosis (RN) with SRS
in the setting of ICIs is an ongoing area of research. We investigated rates
of RN in patients with BM from lung adenocarcinoma treated with SRS
with or without concurrent ICIs. METHODS: We identified 39 patients at
a single institution who underwent SRS treatment for BM from lung adenocarcinoma. Of these, 19 (49%) received SRS without ICIs and 20 (51%)
patients received ICIs within a month of SRS. The rate of RN, defined by
MRI features and histology when available, was compared between each
group using multivariate analysis. Kaplan Meier survival estimates were
calculated based on overall survival and compared to median survival predicted by the graded prognostic assessment. RESULTS: Overall survival
for all patients from diagnosis of brain metastases was 16.6 months (range
3.6–45.9) and median survival predicted by the graded prognostic assessment was 13.7 months (range 6.9–26.5). In total 11 (28%) patients developed MRI and/or histologic evidence for RN during the follow-up period; 5
of 20 (25%) from the SRS with ICI group and 6 of 19 (31%) from the SRS
without ICI group. In multivariate analysis, ICI treatment had no significant impact on rates of RN between groups (OR 0.72 [95% CI: 0.17–2.93];
p=0.65) while bevacizumab treatment was associated with a decreased RN
risk (OR 0.88 [95% CI: 0.43–0.99]; p=0.02). CONCLUSION: Retrospective analysis of patients with BM from lung adenocarcinoma treated
with SRS suggested that administration of ICIs does not increase risk for
development of RN. Further, concomitant treatment with bevacizumab may
decrease risk of RN. These findings suggest that patients with BM from lung
adenocarcinoma can be treated with combination therapy without increased
risk of neurologic toxicity.
32. TREATMENT MONITORING OF IMMUNOTHERAPY AND
TARGETED THERAPY USING AMINO ACID PET IN PATIENTS
WITH BRAIN METASTASES
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Fabian Wolpert3, Jan-Michael Werner1, Martin Hüllner3,
Gabriele Stoffels2, Viola Schweinsberg1, Max Schlaak1, Nicole Kreuzberg1,
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Maike Trommer1, Eren Celik1, Maximilian Ruge1, Martin Kocher1,
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PURPOSE: Recently, the RANO group has analyzed the additional diagnostic value of amino acid PET in patients with primary and secondary
brain tumors and recommended the use of this imaging technique in addition to conventional MRI. Here, we investigated the value of PET using
the radiolabled amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET) for
treatment monitoring of immune checkpoint inhibition (ICI) or targeted
therapy (TT) alone or in combination with radiotherapy in patients with
brain metastases (BM) since contrast-enhanced MRI often remains inconclusive. METHODS: We retrospectively identified 40 patients with 107 BM
secondary to melanoma (n=29 with 75 BM) or non-small cell lung cancer
(n=11 with 32 BM) treated with ICI or TT who had FET PET (n=60 scans)
for treatment monitoring from 2015–2019. The majority of patients (n=37;
92.5%) had radiotherapy during the course of disease. In 27 patients, FET
PET was used for the differentiation of treatment-related changes from BM
relapse following ICI or TT. In 13 patients, FET PET was performed for response assessment to ICI or TT using baseline and follow-up scans (median
time between scans, 4.2 months). In all lesions, static and dynamic FET PET
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